key: cord-0739236-0kqlxx26
authors: Onodera, Taishi; Kita, Shunsuke; Adachi, Yu; Moriyama, Saya; Sato, Akihiko; Nomura, Takao; Sakakibara, Shuhei; Inoue, Takeshi; Tadokoro, Takashi; Anraku, Yuki; Yumoto, Kohei; Tian, Cong; Fukuhara, Hideo; Sasaki, Michihito; Orba, Yasuko; Shiwa, Nozomi; Iwata, Naoko; Nagata, Noriyo; Suzuki, Tateki; Sasaki, Jiei; Sekizuka, Tsuyoshi; Tonouchi, Keisuke; Sun, Lin; Fukushi, Shuetsu; Satofuka, Hiroyuki; Kazuki, Yasuhiro; Oshimura, Mitsuo; Kurosaki, Tomohiro; Kuroda, Makoto; Matsuura, Yoshiharu; Suzuki, Tadaki; Sawa, Hirofumi; Hashiguchi, Takao; Maenaka, Katsumi; Takahashi, Yoshimasa
title: A SARS-CoV-2 Antibody Broadly Neutralizes SARS-related Coronaviruses and Variants by Coordinated Recognition of a Virus Vulnerable Site
date: 2021-08-24
journal: Immunity
DOI: 10.1016/j.immuni.2021.08.025
sha: aad722b147c4eba1395424a37bdd7c830d94cdde
doc_id: 739236
cord_uid: 0kqlxx26

Potently neutralizing SARS-CoV-2 antibodies often target the spike protein receptor binding site (RBS), but the variability of RBS epitopes hampers broad neutralization of multiple sarbecoviruses and drifted viruses. Here, using humanized mice, we identified an RBS antibody with a germline VH gene that potently neutralized SARS-related coronaviruses including SARS-CoV and SARS-CoV-2 variants. X-ray crystallography revealed coordinated recognition by the heavy chain of non-RBS conserved sites and the light chain of RBS with a binding angle mimicking the ACE2 receptor. The minimum footprints in the hypervariable region of RBS contributed to the breadth of neutralization, which was enhanced by IgG3 class switching. The coordinated binding resulted in broad neutralization of SARS-CoV and emerging SARS-CoV-2 variants of concern. Low dose therapeutic antibody treatment in hamsters reduced the virus titers and morbidity during SARS-CoV-2 challenge. The structural basis for broadly neutralizing activity may inform the design of broad spectrum of therapeutics and vaccines.

of avidity effect on the NT-193 IgG affinities. Therefore, the possible impacts of avidity effects on 179 the breadth and neutralizing potency were assessed using The avidity difference between IgG1 and IgG3 subclass could be underestimated by the 181 extremely high-affinity binding under SPR analysis. Moreover, to mimic the low density of RBS hydrogen bonds with RBD (N487) and is also sandwiched between Y489 and F486 ( Figure 4D ). 250

Numerous hydrophobic interactions were observed in the CDR-H3 heavy chain, including those 251 formed by three continuous tyrosines, namely Y103, Y104, and Y105 ( Figures 4E and F) , which 252 recognize the CoV1/2 conserved region. Y104 protrudes deeply to establish -cation 253 interactions with K417 and R403 of RBD and hydrogen bonds with E406 and Q409 ( Figure 4F) . 254

On the other hand, N58 and S56 of CDR-H2 recognize the main chain N atoms of G502 and 255 G504 of the RBD loop ( Figure 4G ). In addition, N52 of CDR-H2 and Y33 of CDR-H1 make 256 hydrogen bonds with D405 ( Figure 4G ). Finally, the CoV2 RBD epitopes recognized by light chain encompasses most of the ACE2-binding site (595 Å 2 surface area is buried), while 258 the CDR-H3 of its heavy chain further mediates the NT-193 anchoring into the CoV-1/2 259 conserved area, presumably relevant for the formation of the closed prefusion trimer, with 498 260 Å 2 surface area buried by heavy chain ( Figure S4C ). This binding mode is in stark contrast to 261 the representative class 1 antibodies, B38 and REGN10933 that mainly rely on heavy chain to 262 cover ACE2-binding sites ( Figures 3F and S5) . Overall, the above-mentioned binding residues 263 of RBD for the interaction with NT-193 are relatively conserved, and functionally maintained 264 within clade 1 sarbecoviruses that include clade 1a (CoV1-related) and clade 1b (CoV2-related) 265 ( Figure 4H ). With the coordinated binding by heavy and light chains, NT-193 is capable of 266 targeting these amino acid residues that are conserved among clade1 sarbecoviruses, resulting 267 in the broad sarbecovirus neutralizing activity ( Figure 3G ). 268

Potential resistance to neutralization escape was evaluated by escape mutation 271 screening in vitro. In this assay, the viruses were passaged up to three times in the 272 VeroE6/TMPRSS2 cell line in the presence of serially diluted IgG1 antibodies ( Figure 5A ). After 273 passaging three times, we observed cytopathic effects (CPEs) by the viruses that escaped from 274 the neutralization by NT-193 IgG1 but not by NT-108/NT-193 cocktail that was set as the control 275 for suppressing the emergence of escape variants ( Figure 5A ). The RBD mutations required for 276 NT-193 escape were determined by viral RNA sequencing from CPE + wells ( Figure 5B ). More 277 than 90% of the sequenced viruses carried a single replacement mutation at position 504 within 278 RBD in two separate experiments. The outcome of escape mutation screening largely depends 279 on initial viral stock and culture condition; therefore, we repeated the experiments using different 280 viral stock and culture condition, and examined whether the same escape mutations are 281 reproducibly isolated or not ( Figure S6A ) (Kobayashi et al., 2008) . We confirmed that the same 282 G504V mutation emerged as a single RBD mutation using NT-193 IgG3 under different 283 screening condition. Whereas the amino acids next to G504 (N501, G502, and Y505) are 284 directly interacting with ACE2 ( Figure 3F ), G504 is not in the ACE-binding site and is located at 285 the outer ledge of the NT-193 heavy chain footprint on the CoV1/CoV2 conserved site (Figures 286 3D, 4G, and 5C), likely enabling escape from heavy chain recognition. The possible impact of 287 the G504V mutation on viral fitness was further assessed using G504V mutant clones, which 288 were confirmed to remain resistant to NT-193 after cloning ( Figure S6B ). G504V mutants poorly 289 replicated in VeroE6 cell lines ( Figure 5D ), and the defect can be at least partly explained by the 290 reduced ACE2 affinity of the G504V RBD relative to that of the parental RBD ( Figure 5E ). Thus, 291 the NT-193-escaping G504V mutation impose a large cost on viral fitness, thereby losing the 292 competitive advantage over circulating CoV2 viruses. This idea is further supported by rare 293 frequency (< 0.001%) of G504V mutation among CoV2 sequences in GISAID database (as of 294

August 3, 2021). 295

CoV2 VOC have recently emerged with potential alternation in pathogenicity, 296 transmissibility, and antigenicity. We then evaluated the cross-neutralizing activity of NT-193 297 against these naturally emerged VOC strains (3 from 501Y.V1 and 2 from 501Y.V3) ( Figure 5F ). 298

The 501Y.V3 strain carries E484K mutation causing a 10-1000-fold reduction in the 299 neutralization activities of RBS antibodies, including REGN10933 and LY-CoV555, upon 300 monotherapeutic usage (Wang et al., 2021b the neutralizing activity to the 501Y.V3 strains below detection limit (IC 50 > 1 g/mL) ( Figure 5F ). 305

The increases in VOC-neutralizing activities have been previously observed in other antibodies, severe body weight loss in the hamsters until day 6 after infection ( Figure 6B ). The prophylactic 328 effects were more pronounced in the 5 mg/kg group than in the 1.25 mg/kg group, and the 329 effects became evident as early as 2 days after infection. The difference in body weight 330 between treated and untreated groups further widened at later time points, resulting in reduced 331 viral genomes and antigens in the lungs at day 6 after infection ( Figure 6C ). Similar to 332

prophylaxis, all therapeutic treatments, including the groups at 1.25 mg/kg dosage, prevented 333 body weight loss in hamsters by day 6 after infection ( Figure 6D ), and reduced the viral 334 genomes and antigens detected in the lungs as well ( Figure 6E ). Although the therapeutic 335 efficacy was slightly attenuated compared with prophylactic efficacy, the efficacy of IgG3 at 1.25 mg/kg dosage was comparable to that provided by REGN10933 IgG3 of the same 337 dosage, which is one of the most potently neutralizing and protective antibodies to original CoV2 In vitro escape mutation screening identified G504 as another key footprint of Recently, in vitro evolution approach with random mutagenesis and selection by yeast display 376 libraries was applied to generate an anti-SARS-related virus neutralizing antibody, ADG-2 377 (Rappazzo et al., 2021) . This engineered process elevated the potency and breadth against 378 SARS-related virus neutralization, and coincidently, the binding mode of this antibody depended 379 on G504. G504V mutation is infrequently detected (< 0.001%) among CoV2 sequences 380 deposited in GISAID database. Together with the attenuated ACE2 binding and replication of 381 G504V mutants, G504 mutations likely lose the competitive advantage over the circulating 382

CoV2 viruses. The low-resolution cryo EM structure showed that ADG-2 recognizes only small 383 portion of ACE2-binding site. Therefore, although NT-193 and ADG-2 share G504 as key 384 footprint, it is important to stress that the NT-193 binding mode totally differs from ADG-2, 385 We thank Akira Dosaka, Eriko Izumiyama, and Ryoko Itami at NIID for technical support. 432

We also thank the beamline staff at Photon Factory and Swiss Light Source for supporting data 433 Dashed lines indicate the humane endpoint (75% weight change). The combined data from 550 more than two independent experiments (n = 5 -12 per group) are shown. Statistical 551 significance is indicated above columns; *, P < 0.05; **, P < 0.01; ***, P < 0.001, ****, P < 0.0001 552 (a two-tailed Mann-Whitney test). TC-mAb mice were established as previously described (Satofuka, 2020) . In brief, an artificial 578 chromosome containing human Ig heavy chain locus (hChr.14) and Ig kappa light chain locus 579 (hCh.2) was generated. The mice carrying the artificial chromosome (IGHK-NAC) were mated 580 with endogenous Ig-knockout strain. All mice were maintained under specific pathogen free 581 conditions and female were used at 6 weeks of age. All work was performed in accordance with 

The human codon-optimized nucleotide sequence coding for the S protein of the CoV2 isolate 594 After blocking with PBS containing 1% BSA, serially-diluted sera, culture supernatants of single 636 cells, or monoclonal antibodies were applied to the plates, and then incubated with goat anti-637 human IgG-HRP (Southern Biotech). HRP-activity was visualized with an OPD substrate 638 (Sigma-Aldrich), and OD490 was measured using an iMark Microplate Reader (Bio-Rad). To 639 examine the polyreactivity, ELISA plates were coated with either 10 g/mL dsDNA of calf 640 thymus (Worthington Biochemical Corporation), 5 g/mL insulin from bovine pancreas, or 10 641 g/mL LPS of E.coli O111:B4 (Sigma-Aldrich). For dsDNA, poly-L-lysine (Wako) was pre-coated 642 at 10 g/mL. After blocking, the plates were loaded with serially-diluted IgG antibodies, and 643 incubated with goat anti-human IgG-HRP, followed by OPD substrate. Indirect 644 immunofluorescence assay using HEp-2 cell line was performed using HEp-2 IFA kit according 

Exposure of an occluded 844 hemagglutinin epitope drives selection of a class of cross-protective influenza antibodies

A serological assay to 848 detect SARS-CoV-2 seroconversion in humans

Extremely potent human monoclonal 851 antibodies from COVID-19 convalescent patients

SARS-CoV-2 escape in vitro from a 854 highly neutralizing COVID-19 convalescent plasma

SARS-CoV-2 neutralizing 857 antibody structures inform therapeutic strategies

REGN-COV2 antibodies prevent and treat SARS-860

CoV-2 infection in rhesus macaques and hamsters

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid 863 mutational escape seen with individual antibodies

Architecture of the SARS 865 coronavirus prefusion spike

Human 867 antilipid A monoclonal antibodies bind to human B cells and the i antigen on cord red blood 868 cells

Potent neutralizing 871 antibodies from COVID-19 patients define multiple targets of vulnerability

Persistence and Evolution of SARS-CoV-2 in an 875 Immunocompromised Host

MolProbity: 878 all-atom contacts and structure validation for proteins and nucleic acids

Antibody evasion by the P.1 strain of SARS-882 CoV-2

Features and development of 884 Coot

Scaling and assessment of data quality

Genomics and epidemiology of 889 the P.1 SARS-CoV-2 lineage in Manaus

Evolution of antibody immunity to 892 SARS-CoV-2

Intra-spike crosslinking overcomes antibody evasion by 895 HIV-1

Multiple SARS-CoV-898 2 variants escape neutralization by vaccine-induced humoral immunity

Effect of Bamlanivimab as Monotherapy or in 901

Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A 902 Randomized Clinical Trial

Studies in humanized mice and convalescent humans yield a 905 SARS-CoV-2 antibody cocktail

SARS-CoV-2 variants B.1.351 and P.1 908 escape from neutralizing antibodies

Discovery of a rich gene pool of bat SARS-related coronaviruses 911 provides new insights into the origin of SARS coronavirus

Syrian hamsters as a small animal model for 914 SARS-CoV-2 infection and countermeasure development

Disentangling 917 primer interactions improves SARS-CoV-2 genome sequencing by multiplex tiling PCR

Structures and distributions of SARS-CoV-2 spike proteins on 922 intact virions

Selection of diverse and clinically relevant 925 integrase inhibitor-resistant human immunodeficiency virus type 1 mutants

VarScan 2: somatic mutation and copy number 929 alteration discovery in cancer by exome sequencing

Inference of macromolecular assemblies from crystalline 931 state

Fast and accurate short read alignment with Burrows-Wheeler 933 transform

The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity

Macromolecular structure determination using 939

X-rays, neutrons and electrons: recent developments in Phenix

Correlates of protection against SARS-CoV-2 in 943 rhesus macaques

A SARS-like cluster of 946 circulating bat coronaviruses shows potential for human emergence

SARS-like WIV1-CoV poised 949 for human emergence

The peripheral T cell population is associated with 952 pneumonia severity in cynomolgus monkeys experimentally infected with severe acute 953 respiratory syndrome coronavirus 2. bioRxiv

Mapping Neutralizing

Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-957 Guided High-Resolution Serology

Cross-neutralization of SARS-CoV-2 by a human 960 monoclonal SARS-CoV antibody

Broad and potent activity against 963 SARS-like viruses by an engineered human monoclonal antibody

CoV-AbDab: the 965

IgG3 enhances 968 neutralization potency and Fc effector function of an HIV V2-specific broadly neutralizing 969 antibody

Convergent antibody responses to SARS-972

CoV-2 in convalescent individuals

Isolation of potent SARS-CoV-2 neutralizing antibodies and 975 protection from disease in a small animal model

Clonal evolution and antigen 978 recognition of anti-nuclear antibodies in acute systemic lupus erythematosus

Efficient human-like antibody repertoire and 981 hybridoma production in trans-chromosomic mice carrying megabase-sized human 982 immunoglobulin loci

Immunoglobulin G3 from polyclonal human immunodeficiency virus (HIV) immune globulin is 985 more potent than other subclasses in neutralizing HIV type 1

A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

Dual recognition of lipid 990 A and DNA by human antibodies encoded by the VH4-21 gene. A possible link between 991 infection and lupus

Prospective mapping of viral mutations that escape antibodies used to 994 treat COVID-19

Reduced neutralization of SARS-CoV-2

1.1.7 variant by convalescent and vaccine sera

Detection of a SARS-CoV-2 variant of concern 1000 in South Africa

Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR 1003 and expression vector cloning

Assessing transmissibility of SARS-CoV-2 1006 lineage B.1.1.7 in England

Unexpected Receptor Functional Mimicry Elucidates 1009 Activation of Coronavirus Fusion

Ultrapotent antibodies against diverse and highly 1012 transmissible SARS-CoV-2 variants

Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7

Predominant autoantibody production by early human B cell precursors

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients 1021 with Covid-19

Escape from neutralizing 1024 antibodies by SARS-CoV-2 spike protein variants

D614G Spike Mutation Increases SARS 1027

CoV-2 Susceptibility to Neutralization

SARS-CoV-2 1030 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

Human neutralizing antibodies against SARS-CoV-2 require 1034 intact Fc effector functions for optimal therapeutic protection

Overview of the CCP4 suite and current 1037 developments

Extrafollicular B cell responses correlate 1040 with neutralizing antibodies and morbidity in COVID-19

1042 (2020a). A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 1043 and SARS-CoV

Structural basis of a shared antibody response to SARS-CoV-2

Recognition of the SARS-CoV-2 receptor 1048 binding domain by neutralizing antibodies

SARS-CoV-2 spike-protein D614G mutation 1051 increases virion spike density and infectivity

Evidence of escape of SARS-CoV-2 variant 1054 B.1.351 from natural and vaccine-induced sera

Compromised Humoral Functional Evolution Tracks

CoV-2 Mortality

Rapid isolation and profiling of a diverse panel 1060 of human monoclonal antibodies targeting the SARS-CoV-2 spike protein

J o u r n a l P r e -p r o o f

The kinetics of ACE2 binding to CoV2-RBD was determined using an OctetRED96e system 740 (ForteBio) at 30°C with shaking at 1,000 rpm. Biotinylated RBDs were loaded at 5 μg/mL in 1× 741 kinetic buffer (0.1 % BSA and 0.02 % Tween-20 in PBS) for 600 s onto streptavidin biosensors 742 (ForteBio) and incubated with serially diluted hACE2 (60, 20, 6.7, 2.2, 0.74, and 0 nM) 743 

Antibody escape mutants were selected using two methods. For the first method, 766VeroE6/TMPRSS2 cells were seeded in 12-well plates (TPP), and a mixture of diluted 767 antibodies and 1000 TCID50 of the CoV2 strain was added to the cells following 1 h culture at 768 37°C. After culturing for 4 days, the cells were monitored for CPE, and the culture supernatant 769 from the well exhibiting evident CPE at the highest antibody concentration was used for the next 770 round of selection and sequencing. For sequencing, total RNA was extracted from culture